2024 saw BONESUPPORT further accelerate its market leadership with Q4 sales reaching SEK257m—up 49% YoY—driving FY sales to SEK898.7m (52% YoY), in line with guidance of 50% topline growth. In North America, CERAMENT G continued its strong performance, rising by approximately SEK22m QoQ to reach ar
BONESUPPORT shares have dropped by 15% YTD, driven by profit-taking ahead of FY 2024 earnings on February 25, coupled with concerns over a reported adverse event involving CERAMENT BVF. We believe the market reaction is overblown, largely fueled by retail sentiment. The event resulted from off-labe
Yesterday, during trading hours, BONESUPPORT announced impressive long-term data on CERAMENT's capabilities in managing bone infections associated with diabetic foot ulcers (DFUs), a condition of growing prevalence due to the rising incidence of diabetes. The study, involving 105 patients, demonstr
BONESUPPORT trades at a premium on EV/Sales and EV/EBITDA to peers, yet a valuation justified by its unique market positioning. The company leads the ortho-biologics market without competition for its antibiotic-eluting CERAMENT products. Beyond its proprietary technology, BONESUPPORT consistently
A director at Bonesupport Holding AB sold 59,407 shares at 325.000SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Q3 2024 followed a similar trend to the first half of the year, with CERAMENT G leading revenue generation. Exceeding expectations, CERAMENT G grew by SEK 25m QoQ in the US, reaching SEK 132m, as the company rapidly secures new hospital agreements. However, CERAMENT BVF saw a slight decline, with U
At the EBJIS 2024 conference, we had the pleasure of hearing firsthand the remarkable top-line SOLARIO study results presented by Prof. Martin McNally, a well-known KOL in the bone infection industry. Involving 500 patients with orthopaedics infections, with 1-year follow-up, the study aimed at ass
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.